
RENALYTIX AI PLC LS-,0025
Acción · GB00BYWL4Y04 · A2N765 (XLON)
0,07 GBP
Precio de cierre XLON 06.06.2025:
7,17 GBX
London (XLON) · Precios actuales y gráficos en MoneyPeak
06.06.2025 14:10
Cotizaciones actuales de RENALYTIX AI PLC LS-,0025
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() London |
RENX.L
|
GBX
|
06.06.2025 14:10
|
7,17 GBX
| 7,32 GBX
-2,12 %
|
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -10,44 % | -10,55 % | -22,12 % | -9,87 % | -56,58 % | -98,41 % |
Firmenprofil zu RENALYTIX AI PLC LS-,0025 Aktie
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Investierte Fonds
Folgende Fonds haben in investiert: RENALYTIX AI PLC LS-,0025 investiert:
Fonds | Vol. in Mio 593,21 | Anteil (%) 0,10 % |
Unternehmensdaten
Name RENALYTIX AI PLC LS-,0025
Firma Renalytix Plc
Website
https://renalytix.com
Heimatbörse
London

WKN A2N765
ISIN GB00BYWL4Y04
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Healthcare Information Services
CEO Mr. James R. McCullough M.B.A.
Marktkapitalisierung 26 Mio
Land Vereinigte Staaten von Amerika
Währung GBP
Mitarbeiter 0,1 T
Adresse 1460 Broadway, 10036 New York
IPO Datum 2018-11-06
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 2O9.F |
London | RENX.L |
Weitere Aktien
Investoren die RENALYTIX AI PLC LS-,0025 die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.